**METABOLIC DISORDERS**

**FP124**

**INSIGHTS INTO THERAPEUTIC MECHANISMS OF L-ARGININE THERAPY IN MELAS SYNDROME USING EXERCISE TESTING WITH CYCLE ERGOMETRY AND 31P-MRS OF MUSCLE**

Lance H. Rodan1, Greg Wells 1,2, Laura Banki3, Sara Thompson1, Jane Schneiderman 1,3, Ingrid Ten1. Division of Neurology, Dept. of Pediatrics, Hospital for Sick Children; University of Toronto; 1Physiology and Experimental Medicine, Hospital for Sick Children, Toronto; Faculty of Kinesiology and Physical Education, University of Toronto, Canada

**Background:** MELAS syndrome is associated with myopathy and exercise intolerance in addition to stroke-like episodes (SLEs). Recent work has demonstrated a beneficial effect of L-arginine therapy for treatment and prevention of SLEs. The purpose of this study was to evaluate the effects of arginine supplementation on muscle metabolism in vivo in patients with MELAS syndrome in an attempt to better understand the treatment effects of arginine.

**Methods:** We enrolled 3 siblings with MELAS syndrome and 4 controls. We employed case control methodology for comparison of baseline exercise parameters on 31P-MRS of muscle and graded cycle ergometry. We used a clinical trial study design to assess response of these parameters to single dose and 6 week steady-state L-arginine.

**Results:** 31P-MRS of muscle: At baseline, phosphocreatine (PCr) levels were elevated in MELAS subjects (p=0.05), ATP levels were decreased (p=0.01), and PCR/ATP ratio was elevated (p=0.01). The concentration of magnesium was lower in MELAS subjects (p=0.0001). Following L-arginine therapy, MELAS subjects demonstrated increased Pi/PCr (p=0.01), and PCr/ATP ratio was elevated (p=0.01). One subject showed an extraordinary improvement in phosphocreatine recovery. Graded cycle ergometry: At baseline, mean percentage of VO2 max reached during exercise was lower in MELAS subjects (p=0.04). L-arginine therapy increased the percentage of maximum work at anaerobic threshold (p=0.037).

**Conclusions:** L-arginine supplementation produces a benefit in muscle metabolism in MELAS syndrome based on laboratory exercise testing. The mechanisms underlying these improvements are not yet elucidated, and may include improved bioenergetics and/or improved perfusion.

**FP125**

**METHYLMALONIC ACIDEMIA: DIAGNOSIS AND LONG-TERM OUTCOME**

Juliana Barbosa de Pádua Pinheiro1, Elisa Victoria Costa Caetano1, Patricia Guikhen Takahashi1, Samuel Borges de Oliveira1, Poliyanna Barbosa Lima Cenqueria1, Flavia Piazzon1, Clássia Bueno1, Fernando Kok1, Umbertina Conti Reed1. Hospital das Clínicas da Universidade de São Paulo, Brazil

**Introduction:** Methyhamonic acidemias (MMA) are a heterogeneous group of inborn errors of branched-chain amino acids and of other propionic substrates metabolism, which are characterized by the accumulation of methyhamonic acid in many body fluids. The disease is caused by a defect of the enzyme methylaminol-CoA mutase or by one of the defects in the metabolism of its cofactor, cobalamin (B12). This study aims to describe the evolution of 13 patients with MMA in Brazil, with emphasis on long-term outcome.

**Methods:** Retrospective observational study was performed in Neurometabolic Diseases outpatient of HCFMUSP Pediatric Neurology Department, assessing demographics features, age at diagnosis, clinical manifestations, exams results, treatment and complications.

**Results:** The mean follow-up time was 4 years (5m-12y). Median age at diagnosis was 25 months, which was 12 months for B12 non responders and 31 months for responsive forms. Recurrent vomiting were present in 92% of the sample; hypotonia and development delay in 100% of vitamin B12 non responders and combined with homocystinuria forms. The median values of plasma methylaminolactic acid was 464.5 in vitamin B12 responders patients, 1218.9 in vitamin B12 non responders and 1337 in combined with homocystinuria forms.

**Conclusion/Discussion:** The diagnosis in done lazily in Brazil. The vitamin B12 non-responders patients showed earlier onset of symptoms. In non-responders and combined with homocystinuria cases, development delay was more frequent than in cobalamin responders.

**FP127**

**COENZYME Q10 DEFICIENCY: CLINICAL AND BIOCHEMICAL CHARACTERIZATION**

Juliana Harumi Araújo1, José Luc Pedrosi1, Marcelo Rodrigues Mauro1, Orlando Graziani Povoa Barottini2, Claudia Cristina Ferreiro1, Universidade Federal de São Paulo, Brazil; 1Universidade Federal de São Paulo, Brazil, 1Instituto Israelita de Ensino e Pesquisa Albert Einstein, Brazil; 2Universidade Federal de São Paulo, Brazil, 1Universidade Federal de São Paulo, Brazil; 2Instituto Israelita de Ensino e Pesquisa Albert Einstein, Brazil

**Introduction:** Coenzyme Q10 (CoQ10) deficiency is a mitochondrial disorder with clinical and genetic heterogenous presentations. Encephalomyopathy with recurrent myoglobinuria, severe infantile multisystemic disease, cerebellar ataxia, isolated myopathy and nephrotic syndrome are the main phenotypes described. The aim of this study is to identify patients with suspected CoQ10 deficiency and perform their clinical and biochemical characterization.

**Methods:** Twenty suspected patients between 0-10 years old were selected and submitted to clinical and laboratorial investigation. Fibroblast cell lines acquired from skin biopsies were submitted to chromatographic analysis and the Ultimate 3000 High Performance Liquid Chromatography measured CoQ10 levels. Mitochondrial redox state and enzyme activity from complexes I-III were analysed.

**Results:** Eleven patients (53%) had low CoQ10 concentrations. Two patients had isolated myopathy and showed 76% and 65% of CoQ10 residual content. Two patients had Leigh Syndrome and showed 60% and 98% of CoQ10 residual content. One patient had atypical clinical symptoms and 82% of CoQ10 residual content. Six patients had cerebellar ataxia and variable CoQ10 residual content, ranging from 52% to 92%. A significant increase in fibroblast levels of reactive oxygen species (ROS) was observed in 8 patients, suggesting bioenergetic deficiency.

**Conclusion/Discussion:** The diagnosis in done lazily in Brazil. The vitamin B12 non-responders patients showed earlier onset of symptoms. In non-responders and combined with homocystinuria cases, development delay was more frequent than in cobalamin responders.
**Discussion:** Heterogeneity in CoQ10 content and ROS production observed in our population might be directly related to differences in clinical presentation and mutations between patients.

**Conclusion:** Characterization of CoQ10 deficiencies with clinical and biochemical features may help us understand and improve diagnosis. Once it is a treatable condition, early detection may change prognosis.

**FP128**

**MELAS SYNDROME IS ASSOCIATED WITH IMPAIRED CEREBROVASCULAR REACTIVITY AND CEREBRAL HYPERPERFUSION IN BETWEEN STROKE-LIKE EPISODES**

Lance H Rodan1, Julian Poublanc2, Olivia Pucci2, Joseph A Fisher1, Tien Wong5, Eugen Hlasny2, David Mikulis1, Ingrid Ten1. Division of Neurology, Dept. of Pediatrics, Hospital for Sick Children; University of Toronto; Dept. of Medical Imaging, The Toronto Western Hospital; University of Toronto; Dept. of Anesthesiology, University Health Network; University of Toronto

**Background:** Stroke-like episodes constitute a major source of morbidity and mortality in MELAS syndrome. The pathophysiology of these episodes is incompletely understood, but is presumed to involve both direct neuronal injury and functional angiopathy as a result of mitochondrial energy failure. We performed a case control study using Blood Oxygen Level Dependent (BOLD) fMRI to evaluate baseline cerebral blood flow (CBF) and arterial cerebrovascular reactivity (CVR).

**Methods:** We enrolled 3 siblings with MELAS syndrome (A3243G mtDNA) with varying percentages of mutant mtDNA and 4 healthy age and gender-matched controls. CBF was calculated using arterial spin labelling methodology. For CVR studies, subjects were fitted with an air-tight sequential gas delivery mask with gas delivery controlled using the RepiAct sequencer. Subjects were given a series of four CO2 challenges where PaCO2 was raised 10 mmHg above their baseline with PaCO2 maintained at 100 mmHg.

**Results:** MELAS subjects demonstrated increased CBF and decreased CVR compared to controls, and the degree of abnormality correlated with disease severity and percentage of mutant mtDNA in blood. On regional analysis, mean CVR was reduced to a greater degree in the frontal compared to the occipital cortices.

**Discussion:** Patients with MELAS syndrome have impaired CVR and cerebral hyperperfusion in between stroke-like episodes, lending credence to a vascular and/or hemodynamic contribution to the latter. CBF and CVR may serve as prognostic markers to stratify risk for stroke-like episodes.

**FP130**

**MITOCHONDRIAL DNA DISEASE: CLINICAL SPECTRUM FROM THE GENOTYPE TO THE PHENOTYPE**

Paola Santander, Monica Troncoso, César Mateluna, Andrés Barrios, Patricio Guerra-Ana Fernández-Royo, España Barrios, Francisa Millán. Department of Pediatric Neuropsychiatry Hospital San Borja Arrarán - Universidad de Chile, Chile

**Introduction:** Mitochondrial diseases are a group of maternally inherited disorders, clinically heterogeneous produced by mitochondrial DNA mutations. Clinical features related to a specific mutation are usually variable and multisystemic.

**Aim:** To evaluate clinical manifestations, genogram, testing and evolution of patients diagnosed in our center with mitochondrial diseases and their phenotypic characteristics in relation to the genotype with different point mutations of mitochondrial DNA (A3243G, G11778A, A8344G).

**Methods:** Retrospective descriptive and monitoring of all patients with mitochondrialDNA mutations confirmed. Review of clinical records. Results: 45 patients were studied 9 present with A3243G mutation 33 G11778A mutation and 3 A8344G mutation. In patients with A3243G mutation, average age of onset symptoms was nine years: headache (5/9), stunting (9/9), sensorineural deafness (8/9), cardiac disorders (2/9). They present stroke-like episodes (9/9) between 6 to 21 years, generalized tonic-clonic seizures (9/9). Study: elevated lactic acid plasma-CSF relation (9/9), ragged-red fibers (RRF)(7/9), CT/ MRI: basal ganglia calcification (8/9), areas of infarction (stroke like) temporoccipital (9/9). Evolution: progressive, 3 died. Their relatives were affected by deafness, diabetes, and heart disease. 33 patients with G11778A mutation, 12 symptomatic. Presentation mean age 18 years, visual impairment (9/12), optic atrophy (7/12), impaired gait (4/12), dystonia (3/12), CT/ MRI: putamens necrosis (4/12). Evolution: stable (5/12), slow progressive (7/12). 3 brothers with A8344G mutation, average age presentation 10.6 years: all with myoclonic epilepsy, neuropathy, ataxia and FRR (+). Evolution: progressive.

**Conclusions:** In our series, A3243G mutation was related to mitochondrial dysfunction with lactic acidosis and stroke-like episodes (MELAS) phenotype, G11778A mutation with Leber's optic neuropathy (LHON) phenotype and mutation A8344G with myoclonic epilepsy with ragged red fibers (MERRF) phenotype. Clinical manifestations, tests and maternally inherited form were the classically described for these phenotypes.
presented mild, two moderate and eight severe disability. Cerebral RM in acute episode showed basal ganglia and white matter compromise, bifrontotemporal atrophy, progressing to striatal atrophy. Residual enzymatic activity was deficient in four patients who were studied. Mutations found were heterozygous to R16Q/R402W, Y113H/R161Q, Y113H/R402W, V133H/385Y and homozygous to R402W/R402W, A293T/A293T, Y113H/Y113H. No relationship was found between neurologic severity and specific genotype.

**Conclusion:** In our series, the most frequent presentation was an encephalitis-like episode. The most invalidating symptoms were extrapyramidal and neuroimaging were distinctive. The homoygous and heterozygous mutation in Y113H and R402W are frequent in Chilean population, being Y113H exclusive in this population. The biochemical genotype and phenotype did not predict clinical course. In conclusion, presymptomatic diagnosis of this affection allows an appropriate management with a favourable evolution.

**FP132**

**CONGENITAL METABOLISM DISEASES OF NEUROTRANSMITTERS IN PEDIATRIC NEUROLOGY: CLINICAL DESCRIPTION AND NEUROLOGICAL TRACING OF A GROUP OF PATIENTS.**

Monica Troncoso, Paola Santander, Carla Rubilar, Valentina Micolich, Carla Rojas, Rodrigo Diaz, Doris Leon, Francisca Faure, Ledia Troncoso. Servicio Neurología Infantil Hospital San Borja Arriarán, Universidad de Chile, Santiago Chile.

**Introduction:** The neurochemical manifestations of congenital metabolism diseases of amineergic neurotransmitters (NT) are diverse. The autosomal dominant Dopa-responsive dystonia (DRD), with deficiency of GTP cyclohydrolase1 (GTPCH1), is the most common type, with a satisfactory response to treatment. We describe clinical features, response to treatment and outcome of patients diagnosed with inborn errors of amineergic neurotransmitters in our center.

**Methods:** A retrospective descriptive study and a prospective follow-up of 17 patients. Review of clinical records.

**Results:** 17 patients: 16/17 exhibit DRD. 12/16 women. On 9/16 the average was 5 years age at onset and 9.5 years at diagnosis. In all patients the initial symptom was gait disturbance with diurnal fluctuation, lower limb (8/9) and upper limb (8/9) dystonia, trunk dystonia (3/9), tremor (2/9). Adult relatives (7/16) begin symptoms between 20 and 40 years:

- Limb (8/9) and upper limb (8/9) dystonia, trunk dystonia (3/9), tremor
- The initial symptom was gait disturbance with diurnal fluctuation, lower limb (8/9) and upper limb (8/9) dystonia, trunk dystonia (3/9), tremor
- Adult relatives (7/16) begin symptoms between 20 and 40 years
- The mode of inheritance was autosomal (3/9). Adult relatives (7/16) begin symptoms between 20 and 40 years

**Conclusion:** In our series predominates DRD, with clinical features and therapeutic response of chaperone therapy in nGD.

**FP133**

**CLINICAL PROFILE OF CHILDREN WITH BIOTINIDASE DEFICIENCY AND RESPONSE TO ORAL BIOTIN THERAPY: EXPERIENCE FROM A DEVELOPING COUNTRY**

Pratibha Singh1, Arushi Gahlot Saini1, Puneet Jain1, Savita Attri1, Renu Suthar1, Jitendra Kumar Sahu1, Naveen Sanikhyan2, N Khandelwal2. 1Post Graduate Institute of Medical Education And Research, Chandigarh 160012, India; 2Lady Harding Medical College and associated Kalawati Saran Children’s Hospital, New Delhi, India, India

**Aim:** To study the clinical profile of children with biotinidase deficiency and their response to oral biotin.

**Methods:** Twenty-six consecutive patients with biotinidase deficiency diagnosed from September 2004-2013 were retrospectively reviewed. Initiation of biotin treatment was considered early (<6 months) and late (>6 months of age); responses were compared.

**Results:** Mean age at symptom-onset was 7.7 months (10 days-48 months). Developmental delay (65%), neuroregression (58%), seizures (81%), skin changes (65%), scanty hair (69%) and characteristic rash (31%) were noted at presentation. Generalized tonic-clonic seizures were (61.5%) preponderant. Microcephaly was seen in 33% and hypotonia in 65%. One child had macrocephaly. Perinatal-period was normal in 80%; one child had parental consanguinity. Common electroencephalography abnormalities were generalized spikes/spike-wave-complexes (31%), burst-suppression (15%), focal slowing (11%) and hypersynchrony (3%). Common magnetic-resonance-imaging abnormalities were diffuse cerebral atrophy (31%), delayed myelination (8%) and non-specific white-matter hyperintensities (8%). Mean serum biotinide level was 2.28 nmol/min/ml (range 0.08-5 nmol/min/ml). Oral biotin 10-20 mg/day was initiated in all patients; 50% were in early-treatment group. Mean follow-up period was 33.5 months. One patient was vegetative at 9 years of age and two patients died; 77% patients symptomatic relief following biotin therapy. Neurological sequelae noted were intellectual impairment, developmental delay, seizures, hyperactivity and vision-hearing impairments. Poorer seizure control (70% vs 85%), developmental delay (62% vs 70%) and hyperactivity (77% vs 92%) were noted in late vs early-treatment groups respectively.

**Conclusion:** Early recognition and prompt initiation of long-term biotin therapy helps in early seizure control and improved neurological outcomes.
Aim: To report on a large cohort of patients with 2-hydroxyglutaric aciduria diagnosed at KFSHRC.

Methods: Random urine samples from Saudi children with static as well as progressive neurodevelopmental disorders were evaluated by GC-MS analysis followed by LC-MS/MS chiral analysis of the D and L enantiomers of 2-hydroxyglutaric acid.

Results: Since 1995 and among 3197 samples which were abnormal for various inborn errors of metabolism, 27 patients (8.4/1000) with significant 2-hydroxyglutaric aciduria were identified. Chiral analysis confirmed L-2HGA (15 patients), D-2HGA (3 patients) and combined D, L-2HGA (5 patients). One patient had D2-HGA in combination with 4-hydroxybutyric aciduria.

Conclusion: L-2HGA is more common among Saudi patients with 2HGA. D-2HGA in combination with 4-hydroxybutyric aciduria likely results from altered activity of ALDHFE1 in combination with recessive germline mutations in SSADH. Accurate diagnosis of the specific etiology of 2HGA is essential for proper management, prognosis, genetic counselling and more recently, potential enrolment in prospective clinical trials.

FP136
MITOCHONDRIAL MOLECULAR GENETIC MUTATIONS FOUND IN A SOUTH AFRICAN POPULATION 1992-2012
Gillian Tracy Riordan. University of Cape Town, Health Sciences Faculty, South Africa

There is little known or published about the prevalence of primary mitochondrial respiratory chain disease in Africa, owing to resource restraints and the necessary prioritisation of health funding for preventable disease.

Aim: To review the pattern of common mitochondrial genetic mutations identified in a genetically diverse South African population from 1992-2012.

Method: PCR analysis and standard methods of restriction enzyme digestion and/or sequencing of mitochondrial and autosomal DNA from blood, fibroblasts, urine and or muscle were performed as part of clinical diagnostic service.

Results: There were 907 referrals for analysis. 211 (23%) samples were from persons of indigenous African ancestry; the remainder were of European or mixed descent. Sixty three patients had mutations (7%). The most common was mt.3243A>G, MELAS (n=17). Mt.8993T>C NARP occurred in 9 patients, 8 from the same mixed ancestry family. Unusual mutations included Leigh Syndrome (LS) with mt.13094T>C, LS with mt.14597T>C, and two unrelated children found to be compound heterozygous for a known splice site mutation (c.751+6T>G) and an undescribed p.56 Ala>Gly in exon3 of the Surf1 gene. 5/10 (50%) of patients with common deletions and 5/53 (9%) patients with point mutations had indigenous African ancestry. The incidence of positive test results was 4.7% (10/211) in the African sub population compared with 7.5% (53/706) in the rest of the group.

Conclusion: There is a trend for presentation with common deletions to be more prevalent than common point mutations in this Sub Saharan indigenous African population. Further research is indicated to validate these observations.